相似文献
1
Managing Hypertension in Patients with CKD: A Marathon, Not a SPRINT.
J Am Soc Nephrol. 2016 Jan;27(1):40-3. doi: 10.1681/ASN.2015101125. Epub 2015 Nov 9.
2
In the Wake of Systolic Blood Pressure Intervention Trial: New Targets for Improving Hypertension Management in Chronic Kidney Disease?
Nephron. 2017;135(4):287-290. doi: 10.1159/000455130. Epub 2017 Feb 4.
3
How Low Do We Go (in the Post-SPRINT Era)?
Adv Chronic Kidney Dis. 2019 Mar;26(2):110-116. doi: 10.1053/j.ackd.2019.01.007.
4
[Managing hypertension in patients with chronic kidney disease - implications of the SPRINT study].
Wiad Lek. 2016;69(5):742-744.
5
[The results of SPRINT study from the point of nephrology].
Vnitr Lek. 2016 Winter;62 Suppl 6:55-57.
6
7
[New aspects of hypertension management in patients with chronic kidney disease].
Rev Med Suisse. 2014 Sep 10;10(441):1668-72.
8
Administration-time-dependent effects of hypertension treatment on ambulatory blood pressure in patients with chronic kidney disease.
Chronobiol Int. 2013 Mar;30(1-2):159-75. doi: 10.3109/07420528.2012.701459. Epub 2012 Oct 25.
9
Hypertension in chronic kidney disease after the Systolic Blood Pressure Intervention Trial: targets, treatment and current uncertainties.
Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii219-ii223. doi: 10.1093/ndt/gfw269.
10
Adherence to antihypertensive agents and blood pressure control in chronic kidney disease.
Am J Nephrol. 2010;32(6):541-8. doi: 10.1159/000321688. Epub 2010 Nov 2.
引用本文的文献
1
Disruption of CXCR6 Ameliorates Kidney Inflammation and Fibrosis in Deoxycorticosterone Acetate/Salt Hypertension.
Sci Rep. 2020 Jan 10;10(1):133. doi: 10.1038/s41598-019-56933-7.
2
Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease.
J Am Heart Assoc. 2019 Aug 20;8(16):e012749. doi: 10.1161/JAHA.119.012749. Epub 2019 Aug 14.
3
Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study.
PLoS One. 2018 Aug 20;13(8):e0202604. doi: 10.1371/journal.pone.0202604. eCollection 2018.
4
Acute Declines in Renal Function during Intensive BP Lowering and Long-Term Risk of Death.
J Am Soc Nephrol. 2018 Sep;29(9):2401-2408. doi: 10.1681/ASN.2018040365. Epub 2018 Jul 13.
5
Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).
Toxins (Basel). 2018 Jun 12;10(6):237. doi: 10.3390/toxins10060237.
6
Renalase Protects against Renal Fibrosis by Inhibiting the Activation of the ERK Signaling Pathways.
Int J Mol Sci. 2017 Apr 27;18(5):855. doi: 10.3390/ijms18050855.
7
Renal Denervation Improves the Baroreflex and GABA System in Chronic Kidney Disease-induced Hypertension.
Sci Rep. 2016 Dec 5;6:38447. doi: 10.1038/srep38447.
8
Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease.
Kidney Int. 2016 Dec;90(6):1348-1356. doi: 10.1016/j.kint.2016.08.009. Epub 2016 Oct 4.
9
CXCL16 Deficiency Attenuates Renal Injury and Fibrosis in Salt-Sensitive Hypertension.
Sci Rep. 2016 Jun 29;6:28715. doi: 10.1038/srep28715.
本文引用的文献
1
Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease.
JAMA Intern Med. 2014 Sep;174(9):1442-9. doi: 10.1001/jamainternmed.2014.3279.
2
The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).
Clin Trials. 2014 Oct;11(5):532-46. doi: 10.1177/1740774514537404. Epub 2014 Jun 5.
3
Long-term effects of intensive glucose lowering on cardiovascular outcomes.
N Engl J Med. 2011 Mar 3;364(9):818-28. doi: 10.1056/NEJMoa1006524.
4
Intensive blood-pressure control in hypertensive chronic kidney disease.
N Engl J Med. 2010 Sep 2;363(10):918-29. doi: 10.1056/NEJMoa0910975.
5
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
N Engl J Med. 2010 Apr 29;362(17):1575-85. doi: 10.1056/NEJMoa1001286. Epub 2010 Mar 14.
6
Treatment of hypertension in patients 80 years of age or older.
N Engl J Med. 2008 May 1;358(18):1887-98. doi: 10.1056/NEJMoa0801369. Epub 2008 Mar 31.
7
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.
J Am Soc Nephrol. 2005 Jul;16(7):2170-9. doi: 10.1681/ASN.2004090763. Epub 2005 Jun 1.
8
Estrogen plus progestin and the risk of coronary heart disease.
N Engl J Med. 2003 Aug 7;349(6):523-34. doi: 10.1056/NEJMoa030808.
9
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
Lancet. 2002 Dec 14;360(9349):1903-13. doi: 10.1016/s0140-6736(02)11911-8.
10
Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
JAMA. 1998 Aug 19;280(7):605-13. doi: 10.1001/jama.280.7.605.
Zotero 插件